Measurement of the concentration of three antituberculosis drugs in the focus of spinal tuberculosis.
This is an experimental study on the distribution of antituberculosis drugs such as rifampin, isoniazid, and pyrazinamide in pathologic vertebrae of spinal tuberculosis in order to provide the regimen of chemotherapy and surgical treatment of spinal tuberculosis. The distribution of antituberculosis drugs in pathologic vertebral tissues matters greatly to the clinical effect of spinal tuberculosis' treatment. However, few pharmacokinetic studies and clinical reports about the concentrations of antituberculosis drugs in vertebral foci have been published so far. Twenty-four patients with spinal tuberculosis were divided into sclerotic group (n = 15) or non-sclerotic group (n = 9) according to radiographic features of lesion. All patients received chemotherapy with 2HRZ/2.5H(2)R(2)Z(2) for a duration of 4.5 months. Four weeks after chemotherapy all patients underwent surgery and the specimen of serum, ilium, and pathologic vertebral tissues, including sclerotic wall, subnormal osseous tissue, and foci were obtained during operation in 120-130 and 180-190 min after oral intake in the morning, respectively. The levels of three drugs in the specimen were measured using HPLC method. The concentration levels of isoniazid, rifampin and pyrazinamide varied greatly in different tissues of spinal tuberculosis, of which the bactericidal concentration values of isoniazid and rifampin and fivefold minimal inhibitory concentration (MICs) of pyrazinamide were found in subnormal vertebral bone and self-contrast ilium, the MICs of all drugs were found in sclerotic wall outside foci, and undetected level was found in foci inside the sclerotic wall. To patients without vertebral sclerotic wall around the foci, the isoniazid in foci was of bactericidal level and rifampin and pyrazinamide in foci corresponded to the MICs respectively. The sclerotic bone of affected vertebra plays an important role in blocking the antituberculosis drug's penetration into tuberculosis focus.
Ge
Zhaohui
Z
Department of Orthopedic Surgery, Hospital of the Ningxia Medical School, Yinchuan, Ningxia, PR China. gezhaohui@gmail.com
Wang
Zili
Z
Wei
Mingji
M
D000328:Adult; D000995:Antitubercular Agents / Q000097:blood / Q000493:pharmacokinetics*; D001706:Biopsy; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000097:blood / Q000493:pharmacokinetics; D008297:Male; D008875:Middle Aged; D011718:Pyrazinamide / Q000097:blood / Q000493:pharmacokinetics; D012293:Rifampin / Q000097:blood / Q000493:pharmacokinetics; D012598:Sclerosis / Q000382:microbiology / Q000473:pathology; D013131:Spine / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D014057:Tomography, X-Ray Computed; D014399:Tuberculosis, Spinal / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D055815:Young Adult
D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin
Chemotherapy. 1984;30(6):358-65
6518835
Zhonghua Jie He He Hu Xi Za Zhi. 1998 Oct;21(10):617-9
11477883
Chemotherapy. 1981;27(3):166-72
7226972
J Pharm Biomed Anal. 1999 Jan;18(6):1013-20
9925337
Clin Radiol. 1993 Mar;47(3):196-9
8472484
Spine J. 2007 Nov-Dec;7(6):671-81
17998127
Acta Orthop Scand. 1977;48(4):362-8
920129